Provectus Pharmaceuticals Terminates Proposed Convertible Preferred Stock Offering

Provectus Pharmaceuticals Terminates Proposed Convertible Preferred Stock Offering

<0> Provectus Pharmaceuticals, Inc.Peter R. Culpepper, CFO, COOPhone: 866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse, DM, SVP – Investor RelationsBill Gordon, SVP – Media RelationsPhone: 212-564-4700 </0>

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, ), a development-stage oncology and dermatology biopharmaceutical company, announces the termination of its proposed convertible preferred stock offering because of current market conditions. Provectus filed a preliminary prospectus supplement with the Securities and Exchange Commission on September 4, 2012, with respect to the proposed offering. As disclosed in the Company's filings with the Securities and Exchange Commission, the Company expects to seek additional financing to fund its operations.

This press release is for informational purposes only and constitutes neither an offer to buy nor a solicitation of an offer to sell the above-described securities or any other securities. This press release shall not constitute an offer, solicitation or sale in any jurisdiction.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, . For additional information about Provectus please visit the Company's website at or contact Porter, LeVay & Rose, Inc.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.